Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.71 |
| ▸ | ECE1 | P42892 | 12/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | MPO | P05164 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31259939 | 1.00 | ACE (0.71) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL29448058 | 1.00 | ACE (0.71) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL10753140 | 1.00 | ACE (0.71) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL30052393 | 0.95 | OPRM1 (0.66) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL29636478 | 0.95 | ACE (0.67) | ACEECE1ALOX15 | |
| SCHEMBL29704583 | 0.95 | ACE (0.67) | ACEECE1ALOX15 | |
| SCHEMBL29377160 | 0.94 | ACE (0.62) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL5583839 | 0.93 | ACE (0.72) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL9596908 | 0.93 | ACE (0.72) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL11855463 | 0.93 | ACE (0.72) | ACEECE1KDM4EMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0234186-A1 | Use of oligopeptids for the treatment of cerebral disorders | Fresenius AG (DE) | 1987-09-02 | — | — | EP | disclosed |